Evidence map›Paper›PMID 34789165›Full record

ArticleBMC genomics2021

Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma.

Hongjin Wu, Weiwei Tian, Xiang Tai, Xuanpeng Li, Ziwei Li, Jing Shui, Juehua Yu, Zhihua Wang, Xiaosong Zhu

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hongjin Wu *The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China.
Weiwei Tian *Yunnan Province Clinical Center for Bone and joint Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China.
Xiang TaiYunnan Province Clinical Center for Bone and joint Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China.
Xuanpeng LiYunnan Province Clinical Center for Bone and joint Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China.
Ziwei LiThe NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China.
Jing ShuiShanghai International Travel Healthcare Center, Shanghai, 200000, People's Republic of China.
Juehua YuThe NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China. juehuayu@gmail.com.
Zhihua WangYunnan Province Clinical Center for Bone and joint Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China. wzh3333@126.com.
Xiaosong ZhuYunnan Province Clinical Center for Bone and joint Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China. 3474137488@qq.com.
Kunming Medical University · CNFirst Affiliated Hospital of Kunming Medical University · CNChina Regenerative Medicine International (China) · CNShenzhen International Travel Health Care Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. Approximately 80% of patients initially diagnosed with locally advanced or metastatic disease survive only 4-11 months after diagnosis. Tremendous efforts have been made toward understanding the biology of PDAC.

resultsIn this study, we first utilized next-generation sequencing technique and existing microarray datasets to identify significant differentially expressed genes between PDAC and non-tumor adjacent tissue. By comparing top significant survival genes in PDAC Gene Expression Profiling Interactive Analysis database and PDAC transcriptome data from patients, our integrated analysis discovered five potential central genes (i.e., MYEOV, KCNN4, FAM83A, S100A16, and DDX60L). Subsequently, we analyzed the cellular functions of the potential novel oncogenes MYEOV and DDX60L, which are highly expressed in PDAC cells. Notably, the knockdown of MYEOV and DDX60L significantly inhibited the metastasis of cancer cells and induced apoptosis. Further RNA sequencing analyses showed that massive signaling pathways, particularly the TNF signaling pathway and nuclear factor-kappa B (NF-κB) signaling pathway, were affected in siRNA-treated cancer cells. The siDDX60L and siMYEOV significantly inhibited the expression of chemokine CXCL2, which may potentially affect the tumor microenvironment in PDAC tissues.

conclusionsThe present findings identified the novel oncogene DDX60L, which was highly expressed in PDAC. Transcriptome profiling through siRNA knockdown of DDX60L uncovered its functional roles in the PDAC in humans.

Indexed as

Carcinoma, Pancreatic DuctalOncogenesPancreatic NeoplasmsBiomarkers, TumorCell Line, TumorGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsTumor MicroenvironmentBiomarkers, TumorFAM83A protein, humanNeoplasm ProteinsCXCL2DDX60LMYEOVOncogenePancreatic ductal adenocarcinoma (PDAC)

Identifiers

PMID34789165
PMCPMC8600871
OpenAlexW3214040707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.